IP
IP
What we have filed, and what we do not claim.
Our own provisional application, filed in the United States, names four inventors. It covers the use of short interfering RNA against the inflammasome and the lipopolymer formulations that carry it.
The underlying lipopolymer transfection chemistry is the subject of separate patents held by its originating company. Delmune does not own those patents and accesses the chemistry under agreement.